Skip to main content
. 2017 Dec 19;68(666):e63–e72. doi: 10.3399/bjgp17X694169

Table 1.

Sample composition and referral type that led most directly to the cancer diagnosis (N = 17 042)

Total of NCDA n (%) TWW n (%) Urgentan (%) Routine n (%) Screening n (%) Emergencybn (%) To private care n (%) Other n (%) Not known n (%)
Total 17 042 (100.0) 8820 (51.8) 745 (4.4) 1346 (7.9) 1237 (7.3) 2818 (16.5) 315 (1.8) 1004 (5.9) 757 (4.4)

Male 8544 (50.1) 4482 (52.5) 436 (5.1) 829 (9.7) 145 (1.7) 1474 (17.3) 187 (2.2) 549 (6.4) 442 (5.2)

Female 8498 (49.9) 4338 (51.0) 309 (3.6) 517 (6.1) 1092 (12.9) 1344 (15.8) 128 (1.5) 455 (5.4) 315 (3.7)

Age group, years
  0–24 198 (1.2) 46 (23.2) 14 (7.1) 16 (8.1) 2 (1.0) 94 (47.5) 4 (2.0) 9 (4.5) 13 (6.6)
  25–49 1705 (10.0) 951 (55.8) 73 (4.3) 162 (9.5) 113 (6.6) 208 (12.2) 67 (3.9) 59 (3.5) 72 (4.2)
  50–64 4144 (24.3) 2144 (51.7) 153 (3.7) 318 (7.7) 561 (13.5) 509 (12.3) 107 (2.6) 201 (4.9) 151 (3.6)
  65–74 4877 (28.6) 2532 (51.9) 228 (4.7) 423 (8.7) 473 (9.7) 655 (13.4) 73 (1.5) 313 (6.4) 180 (3.7)
  75–84 4213 (24.7) 2274 (54.0) 198 (4.7) 326 (7.7) 79 (1.9) 797 (18.9) 42 (1.0) 281 (6.7) 216 (5.1)
  ≥85 1905 (11.2) 873 (45.8) 79 (4.1) 101 (5.3) 9 (0.5) 555 (29.1) 22 (1.2) 141 (7.4) 125 (6.6)

Cancer site
  Bladder 490 (2.9) 308 (62.9) 26 (5.3) 39 (8.0) 2 (0.4) 61 (12.4) 7 (1.4) 25 (5.1) 22 (4.5)
  Brain 265 (1.6) 23 (8.7) 19 (7.2) 11 (4.2) 0 (0.0) 172 (64.9) 4 (1.5) 16 (6.0) 20 (7.5)
  Breast 2714 (15.9) 1533 (56.5) 30 (1.1) 46 (1.7) 918 (33.8) 56 (2.1) 35 (1.3) 50 (1.8) 46 (1.7)
  Cancer of unknown primary 400 (2.3) 137 (34.2) 21 (5.2) 20 (5.0) 3 (0.8) 160 (40.0) 3 (0.8) 25 (6.2) 31 (7.8)
  Colon 1320 (7.7) 543 (41.1) 63 (4.8) 100 (7.6) 122 (9.2) 350 (26.5) 31 (2.3) 57 (4.3) 54 (4.1)
  Endometrial 400 (2.3) 311 (77.8) 14 (3.5) 23 (5.8) 1 (0.2) 26 (6.5) 10 (2.5) 8 (2.0) 7 (1.8)
  Leukaemia 470 (2.8) 96 (20.4) 30 (6.4) 79 (16.8) 4 (0.9) 165 (35.1) 9 (1.9) 45 (9.6) 42 (8.9)
  Liver 272 (1.6) 87 (32.0) 14 (5.1) 23 (8.5) 7 (2.6) 86 (31.6) 4 (1.5) 32 (11.8) 19 (7.0)
  Lung 2132 (12.5) 976 (45.8) 95 (4.5) 89 (4.2) 14 (0.7) 625 (29.3) 9 (0.4) 212 (9.9) 112 (5.3)
  Lymphoma 739 (4.3) 347 (47.0) 57 (7.7) 81 (11.0) 2 (0.3) 143 (19.4) 21 (2.8) 53 (7.2) 35 (4.7)
  Melanoma 836 (4.9) 611 (73.1) 22 (2.6) 113 (13.5) 2 (0.2) 4 (0.5) 16 (1.9) 45 (5.4) 23 (2.8)
  Multiple myeloma 272 (1.6) 84 (30.9) 24 (8.8) 39 (14.3) 3 (1.1) 76 (27.9) 2 (0.7) 23 (8.5) 21 (7.7)
  Oesophageal 447 (2.6) 281 (62.9) 19 (4.3) 35 (7.8) 8 (1.8) 65 (14.5) 5 (1.1) 17 (3.8) 17 (3.8)
  Oral/oropharyngeal 268 (1.6) 160 (59.7) 12 (4.5) 20 (7.5) 0 (0.0) 17 (6.3) 9 (3.4) 19 (7.1) 31 (11.6)
  Other 1582 (9.3) 728 (46.0) 93 (5.9) 194 (12.3) 72 (4.6) 240 (15.2) 32 (2.0) 130 (8.2) 93 (5.9)
  Ovarian 332 (1.9) 192 (57.8) 15 (4.5) 11 (3.3) 1 (0.3) 81 (24.4) 7 (2.1) 11 (3.3) 14 (4.2)
  Pancreatic 460 (2.7) 185 (40.2) 26 (5.7) 30 (6.5) 0 (0.0) 156 (33.9) 8 (1.7) 36 (7.8) 19 (4.1)
  Prostate 2130 (12.5) 1398 (65.6) 92 (4.3) 258 (12.1) 4 (0.2) 112 (5.3) 72 (3.4) 103 (4.8) 91 (4.3)
  Rectal 648 (3.8) 374 (57.7) 28 (4.3) 66 (10.2) 69 (10.6) 58 (9.0) 19 (2.9) 20 (3.1) 14 (2.2)
  Renal 557 (3.3) 290 (52.1) 27 (4.8) 39 (7.0) 5 (0.9) 94 (16.9) 11 (2.0) 61 (11.0) 30 (5.4)
  Stomach 308 (1.8) 156 (50.6) 18 (5.8) 30 (9.7) 0 (0.0) 71 (23.1) 1 (0.3) 16 (5.2) 16 (5.2)
a

Urgent referrals are not for suspected cancer.

b

Includes instances of patient self-referral. NCDA = National Cancer Diagnosis Audit. TWW = 2-week wait, urgent referral for suspicion of cancer.